• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage publications (all current information on this profile has been aggregated automatically from publisher and metadata sources).
  • Wei Nie, Bing Li, Qing-yu Xiu
  • Medicine
  • The Journal of antimicrobial chemotherapy
  • 2014 (First Publication: 1 June 2014)
  • OBJECTIVES Several studies have compared the clinical effect of β-lactam/macrolide (BLM) dual therapy versus β-lactam (BL) monotherapy in community-acquired pneumonia (CAP) patients. However, theContinue Reading
  • Gong-yan Chen, Jifeng Feng, +20 authors Changxuan You
  • Medicine
  • Annals of oncology : official journal of the…
  • 2013 (First Publication: 1 June 2013)
  • BACKGROUND The OPTIMAL study found that erlotinib improved progression-free survival (PFS) versus standard chemotherapy in Chinese patients with advanced EGFR mutation-positive non-small-cell lungContinue Reading
  • Ying-yuan Zhang, Hai-Hui Huang, +30 authors Guo-ming Wu
  • Medicine
  • Journal of infection and chemotherapy : official…
  • 2009
  • Levofloxacin (LVFX), a fluoroquinolone agent, has a broad spectrum that covers Gram-positive and -negative bacteria and atypical pathogens. It demonstrates good clinical efficacy in the treatment ofContinue Reading
  • Xu Zhao, Ju-fang Wu, +9 authors Ying-yuan Zhang
  • Medicine
  • Diagnostic microbiology and infectious disease
  • 2014 (First Publication: 1 October 2014)
  • The objective of this study was to compare the efficacy and safety of levofloxacin 750 mg for 5 days versus 500 mg for 7-14 days intravenous (IV) in the treatment of community-acquired pneumoniaContinue Reading
  • Yang Liu, Ying-yuan Zhang, +22 authors Li-Wen Chang
  • Medicine
  • Journal of microbiology, immunology, and…
  • 2017 (First Publication: 1 December 2017)
  • BACKGROUND/PURPOSE To compare the clinical efficacy and safety of nemonoxacin with levofloxacin in treating community-acquired pneumonia (CAP) in a Phase II clinical trial. METHODS One hundredContinue Reading